Dawson James analyst Jason Kolbert maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report) on November 24 and set a price target of $35.00. The company's shares closed last Tuesday at $16.24. According to TipRanks.com, Kolbert has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.6% and a 35.5% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.80, implying a 123.0% upside from current levels.
https://www.tipranks.com/news/blurbs/dawson-james-maintains-a-buy-rating-on-anavex-life-sciences-avxl?utm_source=advfn.com&utm_medium=referral